Hephaistos-Pharma
Develops third-generation TLR4 agonist small molecules for cancer immunotherapy.
$4.89M Seed ·
Source: startupintros.com
Total raised: $7.06M across 2 sourced rounds
All 2 rounds ↓Signals
Website registeredMar 6, 2018 (8 years old)
Funding rounds
- Seed · $4.89MSource: startupintros.com
- Seed · $2.17MSource: startupintros.com
- Website created
Companies like Hephaistos-Pharma
PPrimmune TherapeuticsSeries B+ · Jan 2026CCellCentric$220M Series B+ · May 2026
SStorm Therapeutics$56M Series B+ · Apr 2026
AAccent Therapeutics$75M Series B+ · Jan 2024
AAllorion Therapeutics$50M Series B+ · Mar 2023
BBlock BiosciencesPre Seed · Mar 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/hephaistos-pharma (get a free API key).